United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 5 minute read Pharma Industry News Amplia Therapeutics (ASX: ATX) shares gain after 31% response rate in pancreatic cancer trial; U.S. Phase 2 greenlit Amplia Therapeutics’ pancreatic cancer trial hits 31% response rate with narmafotinib. Find out how U.S. expansion plans could reshape the biotech’s pipeline. byPallavi MadhirajuJuly 11, 2025